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Atopic dermatitis (AD) is a common, recurrent, chronic inflammatory skin disease that is
a cause of considerable economic and social burden. Its prevalence varies substantially
among different countries with an incidence rate proclaimed to reach up to 20%
of children in developed countries and continues to escalate in developing nations.
This increased rate of incidence has changed the focus of research on AD toward
epidemiology, prevention, and treatment. The effects of probiotics in the prevention and
treatment of AD remain elusive. However, evidence from different research groups show
that probiotics could have positive effect on AD treatment, if any, that depend on multiple
factors, such as specific probiotic strains, time of administration (onset time), duration
of exposure, and dosage. However, till date we still lack strong evidence to advocate
the use of probiotics in the treatment of AD, and questions remain to be answered
considering its clinical use in future. Based on updated information, the processes that
facilitate the development of AD and the topic of the administration of probiotics are
addressed in this review.
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INTRODUCTION
Atopic Dermatitis (AD), also known as eczema, is a chronic inflammatory, relapsing, and non-
contagious skin disease that is known to affect≈20% of children in both developed and developing
countries (Shaw et al., 2011; Deckers et al., 2012). AD represents one’s first allergic reaction
encountered in childhood and is recognized as a precursor for the development of a series of
hypersensitivity reactions such as food allergies, asthma, and allergic rhinitis (Castro-Rodriguez,
2010; Finnbogadóttir et al., 2012; Carlsten et al., 2013; Silverberg and Simpson, 2013). Classical
treatment guidelines for AD include hydrating topical treatment, topical glucocorticosteroids
(Schmitt et al., 2010), topical calcineurin inhibitors, and concurrent adjuvant therapy, which
includes UV radiations (UVA1 and UVB 311 nm) (Williams and Grindlay, 2008; Gambichler et al.,
2009; Majoie et al., 2009). Traditional therapeutic strategies have been efficacious in ameliorating
the symptoms of AD in most patients (Lio et al., 2012). However, a more comprehensive and
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mechanistic understanding of the underlying immunological
processes is needed to instigate the development of novel
applicable treatment approaches for AD.
GENETIC PREDISPOSITION TO AD AND
UNDERLYING IMMUNOPATHOLOGICAL
PROCESS
Atopic dermatitis is a skin disease that is characterized by
compromised skin barrier integrity, heightened inflammatory
response against stimulants, and diminished antimicrobial
responses that incite abnormal inflammation in the skin. The
underlying mechanism and etiology of AD remain unexplored.
AD is a complex skin problem caused by an interplay between
genetic susceptibility and prenatal/postnatal environmental
factors (Williams and Flohr, 2006). Genome wide screens
have linked AD to several chromosomal loci, including 3q21,
5q31, and 11q13 (Lee et al., 2000; Bowcock and Cookson,
2004; Haagerup et al., 2004; Hoffjan and Epplen, 2005). The
candidate genes interestingly encode immunomodulators and
co-stimulatory proteins involved in T-cell activation, as well as
cytokines involved in the regulation of IgE synthesis, such as
interleukin-3, interleukin-4, interleukin-5, interleukin-11, and
the granulocyte–macrophage colony-stimulating factor (GM-
CSF) (Fölster-Holst et al., 1998; Kawashima et al., 1998; Forrest
et al., 1999; Leung and Bieber, 2003). A study identified loss-of-
function non-sense mutations in the filaggrin gene (FLG) that is
associated with AD (Marenholz et al., 2006; Palmer et al., 2006;
Sandilands et al., 2007; Margolis et al., 2013). The FLG encodes a
protein that is responsible for retaining moisture and protecting
the skin from environmental allergens; therefore, it is crucial for
maintaining skin barrier integrity.
Prenatal and postnatal maternal diet, gestational diabetes,
exposure to microorganisms, and allergens are potential risk
factors associated with the onset and development of AD
(Cipriani et al., 2014). Several epidemiological and experimental
evidences support the theory of “hygeine hypothesis” as the
most reasonable explanation for the AD epidemics in last few
decades (Martinez, 2001). The hygeine hypothesis suggests that
changes in immunoregulatory infectious environment and the
patterns of microbial exposure of children that are associated with
Westernized culture are critical factors underlying the increasing
severity and prevalence of atopic disorders. A study conducted
by Strachan (1989) demonstrated an inverse correlation between
sibship size and the subsequent risk of allergy, and it was recently
confirmed by a broad international study involving more than
500,000 children in 52 countries (Strachan et al., 2015). Briefly,
hygiene hypothesis inversely relates the prevalence of allergic
diseases and urban lifestyles, high standard sanitary conditions,
vaccinations, antibiotic administration, and small family size.
Westernized lifestyle scales down infantile exposure to the
allergens, which translates into decreased Th1-driven immune
responses and favors less mature neonatal Th2-mediated immune
systems, which may be the cause of the onset of allergic diseases
(Strachan, 2000).
PROBIOTICS AND PREVENTION OF
ATOPIC DERMATITIS
Probiotics are live microorganisms that, when administered in
sufficient amounts, confer health benefits on the host (Hill et al.,
2014). They barricade the epithelium and mucosal surfaces in
the intestine, thereby preventing the adherence and invasion of
pathogens (Servin and Coconnier, 2003). After birth the host
receives primary microbial stimulus through the installation of
gut microbiota or through exposure to specific bacterial strains.
The establishment of microbial flora in the early postnatal
period activates the innate and adaptive immune system, and
the uninterrupted microbial stimulus serves to mature the gut
mucosal immune system. Early compromised microbial stimulus
may lead to reduced intestinal surface area, incoordination
and alteration in the mucosal intermediary metabolism, a
sensitive mucosal barrier, and a secretory mucosal IgA system
(Gaskins, 1997; Cebra, 1999). An imbalance in Th1/ Th2 immune
response has been related to the pathogenesis of allergic diseases
(Romagnani et al., 1991; Romagnani, 2000; Schmidt-Weber
and Blaser, 2004). Probiotics contribute to regulating allergic
hypersensitivity reactions by suppressing the Th2 mediated
response that helps in balancing Th1/ Th2 immune responses and
by increasing Treg mediated immune responses (Feleszko et al.,
2007; Kim et al., 2012; Kim J.Y. et al., 2013).
A large number of studies have explored the potential
efficacy of probiotics in the prevention and treatment of AD
(Pessi et al., 2000; Kalliomaki et al., 2001; Ouwehand et al.,
2002; Hattori et al., 2003; Matsumoto et al., 2007; Park et al.,
2008; Savilahti et al., 2008; Wickens et al., 2008; Adams, 2010;
Batchelor et al., 2010; Chapman et al., 2011; Wickens et al.,
2012; Morgan et al., 2014), yet the picture remains unclear
and conflicting (Table 1). Lactobacillus rhamnosus GG (LGG)
is the most frequently studied probiotic strain. AD prevention
studies have been carried out on children at high risk of AD,
and probiotic administration was done 2–4 weeks prenatally to
the pregnant mothers and postnatally to the infants for a 1-
year time period (Frei et al., 2015). The epidemiological study
of a cohort from Norway investigated the potential association
between the administration of probiotic milk during pregnancy
and infancy period and the onset or establishment of atopic
diseases such as AD, rhinoconjunctivitis, and asthama. This
study demonstrated an inverse correlation between the intake
of probiotic milk products and the incidence of AD; however,
the certainty of the evidence is low (Bertelsen et al., 2014).
Another study evaluated the impact of Bifidobacterium breve M-
16V and Bifidobacterium longum BB536 administration over the
time period of 1 month prenatally, 6 months during infancy,
and a period of 18 months follow up on the management of
allergic diseases (Enomoto et al., 2014). The study concluded that
the incidence of AD was lower in the probiotic administered
cases than the controls. A study performed by Rautava et al.
(2012) investigated the preventive effects of L. rhamnosus LPR,
B. longum BL999, and L. paracasei ST11, during 2 months
before and after the expected date of delivery. They reported
less episodes of AD in the infants of mothers who received any
of the probiotic supplements compared to the placebo group;
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TABLE 1 | Effect of probiotics (single or mixed culture) on treatment of Atopic Dermatitis (AD) in humans.
Reference Probiotics Outcome
Majamaa and Isolauri, 1997 Lactobacillus rhamnosus strain GG SCORAD score improvement (P = 0.008)
Rosenfeldt et al., 2003 L. rhamnosus + L. reuteri Positive effect of probiotics seen in allergic subjects (P = 0.04)
Kirjavainen et al., 2003 L. rhamnosus strain GG or L. GG SCORAD decrease (P = 0.02)
Viljanen et al., 2005 L. rhamnosus strain GG Positive effect seen only in IgE-sensitized infants (P = 0.036)
Weston et al., 2005 L. fermentum SCORAD decrease (P = 0.03)
Passeron et al., 2006 L. rhamnosus/synbiotics No significant difference between synbiotics and placebo
Sistek et al., 2006 L. rhamnosus + B. lactis Positive effect seen only in food-sensitized children (P = 0.047)
Brouwer et al., 2006 L. rhamnosus strain GG or L. rhamnosus No significant difference between probiotics and placebo
Fölster-Holst et al., 2006 L. rhamnosus strain GG No significant difference between probiotics and placebo
Grüber et al., 2007 L. rhamnosus strain GG No significant difference between probiotics and placebo
Roessler et al., 2008 L. paracasei + L. acidophilus + B. lactis No significant effects of probiotics
Chernyshov, 2009 L. rhamnosus 95%, L. helveticus 5% SCORAD decrease in subjects not used topical steroids was
shown only in probiotic group (P < 0.01)
Gerasimov et al., 2010 L. acidophilus + B. lactis SCORAD decrease (P = 0.001)
Woo et al., 2010 L. sakei SCORAD decrease (P = 0.008)
Cukrowska et al., 2010 L. casei + L. paracasei Clinical improvement seen mostly in children with
IgE-dependent atopic eczema
Gobel et al., 2010 L. acidophilus, or B. lactis/— No beneficial effects observed
van der Aa et al., 2010 B. breve/synbiotics Improvement in IgE-sensitized infants (P = 0.04)
Yoshida et al., 2010 B. breve SCORAD decrease (P = 0.034)
Wu et al., 2011 L. salivarius/ / synbiotics SCORAD decrease at 8 week (P = 0.022)
Farid et al., 2011 mixture/synbiotics SCORAD decrease (P = 0.001)
Gore et al., 2012 L. paracasei or Bifidobacterium No significant difference between probiotics and placebo
Yesilova et al., 2012 Bifidobacterium
bifidum + L. acidophilus + L. casei + L. salivarius
SCORAD decrease (P = 0.0015)
Han et al., 2012 L. plantarum SCORAD decrease (P = 0.0015)
Iemoli et al., 2012 L. salivarius; + B. breve SCORAD decrease (P < 0.001)
Drago et al., 2011 L. salivarius SCORAD decrease (P < 0.001)
Niccoli et al., 2014 L. salivarius LS01 SCORAD and itch improvement
however, there was no difference in skin prick tests among the
experimental groups (Rautava et al., 2012). A number of studies
on LGG suggest that the combination of probiotic strains and
prebiotic mixtures imposes positive effects in terms of preventing
the onset of AD (Kukkonen et al., 2007; Mikael, 2013; Foolad
and Armstrong, 2014). However, strong evidence to support the
effectiveness of the administration of probiotics at a clinical level
remains elusive (Meninghin et al., 2012; Foolad and Armstrong,
2014).
There are studies that state that the use of probiotics is
ineffective in the management of AD. The incidence of AD was
investigated when the infants who had received probiotic strains
of L. salivarius CUL61, L. paracasei CUL08, Bifidobacterium
animalis subspecies lactis CUL34, and Bifidobacterium bifidum
CUL20 reached 2 years of age, and the results were compared
to those of toddlers who had not received the placebo.
The administration of probiotics did not intervene in the
development of AD (Allen et al., 2014).
TREATMENT OF ATOPIC DERMATITIS
Evidence supporting the use of probiotics for the treatment
and prevention of AD is very limited. A restricted amount
of evidence suggests that probiotics can decrease the severity
of AD. A randomized, double-blind, placebo-controlled study
investigated the effects of the use of the L. plantarum CJLP133
strain in the prevention of AD symptoms. The study was
performed for a time period of 12 weeks among children who
were one and 12 years old. It was found that there was an
improvement in AD scores (SCORAD), with a concomitant
decrease in IFN-γ, eosinophil, and Interleukin-4 counts (Han
et al., 2012). Another randomized, double-blind, placebo-
controlled study investigated the use of L. paracasei (LP),
L. fermentum (LF), and LP+LF together in children, and it
was observed that the SCORAD scores were lower in the
group that received probiotics than those of the placebo group
4 months after discontinuing the probiotic treatment (Wang
and Wang, 2015). Woo et al. (2010) compared children who
received L. sakei supplementation to those who received a placebo
in a double-blind, placebo-controlled trial. It was found that
the supplementation of L. sakei was associated with substantial
clinical improvement with concomitant decrease in chemokine
levels (Woo et al., 2010). Previous meta-analyses evaluating the
effects of probiotics on the treatment of AD have resulted in
inconsistent results (Boyle et al., 2008; Lee et al., 2008; Michail
et al., 2008; Kim et al., 2014). Of these meta-analyses, the most
recent one concluded that probiotics significantly improved the
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FIGURE 1 | Proposed mechanism of probiotics in an animal model of AD. Exposure of atopic skin to a potential allergen enhances the expression of thymic
stromal lymphopoietin (TSLP) that is known to activate dendritic cells (DC). Stimulated dendritic cell direct differentiation of naïve T-cell into Th2 cells and Th17 cells
which, are known as the mediators of allergic inflammation in skin. Probiotics could inhibit the allergic inflammation by increasing the population of regulatory T cells
(Tregs) in the mesenteric lymph nodes of patients. These Tregs could migrate to the site of inflammation and suppress the Th2 and Th17 mediated allergic response
or directly reduce the expression of TSLP.
SCORAD index in patients aged 1 year or older with AD (mean
difference,−4.51; [95% CI,−6.78 to−2.24]; Kim et al., 2014), but
the clinical significance of these findings has been questioned, and
therefore, the role of probiotics in the treatment of AD has not
been definitively established.
MECHANISTIC INSIGHTS INTO
FUNCTIONING OF PROBIOTICS
The discovery of Th17 cells as the mediators of allergic
inflammation in a mouse model of asthama superseded the
previous modes of action of probiotics against allergic diseases
(Feleszko et al., 2007). The application of probiotics reduced the
inflammation by suppressing the levels of INF-γ, IL-4, and Th17
cells in splenic CD4 T-cells and increasing the expression of IL-10
and Treg-related cytokines in mesenteric lymph nodes as shown
in Figure 1 (Jan et al., 2012). Probiotics also impose an inhibitory
effect on the maturation of dendritic cells and, therefore, inhibit
naive T-cells from differentiating into Th2 cells, which triggers
inflammation in the skin (Kwon et al., 2010; Weiss et al., 2011).
The differentiation of naïve T cells mediated by dendritic cells are
known to be regulated by thymic stromal lymphopoietin (TSLP),
a process that could be inhibited by probiotics (Weiss et al., 2011).
Kim et al. (2013a,b) confirms the involvement of dendritic cells,
following the transfer of mature dendritic cells in mice, in the
suppression of allergic disease by probiotics.
CONCLUSION
Probiotics for the prevention or intervention of AD is a vast
underestimated area of research; and as a result, there is
no reliable evidence to date that strongly supports their safe
application. In spite of the weak evidence, a considerable number
of clinicians prescribe the use of probiotics for the prevention
of eczema. The regular instillation of probiotics in daily use
at an early age could help in preventing the initiation of
eczema. However, several variables, such as the use of antibiotics,
prenatal and postnatal diet, mode of delivery, and surrounding
allergenic environment in the home, could impact the early-
life colonization of probiotic strains. Nevertheless, the clinical
administration of probiotics may become more widespread if the
remaining questions are answered with strong evidence: what
type of probiotic strain should be used? What dosage and time
of administration should be used? At what time of life is the use
of probiotics more efficacious? And most importantly, should the
use of probiotics be personalized? Current analysis of the role of
probiotics in the prevention of AD reveals that a positive effect
may be related to the type of probiotic strain used, the method of
administration, onset time, as well as the dose size and duration
of treatment. However, these uncertainties need to be further
clarified before corroborating the preventive impact of probiotics
in the prevention and/ or treatment of AD.
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